Improving effect of carteolol on bodyweight and carbohydrate and lipid metabolic responses in the OLETF rat

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 5, 1997, Pages 321-325

  Saitoh, Yuichi ^a   Tani, Takeshi ^a   Asahi, Yoshihiko ^a   Man, Zhiwei ^a   Kawano, Kazuya ^a   Ikunaga, Hideyuki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

carteolol; glucose; non insulin dependent diabetes mellitus; obesity; OLETF rat; triglyceride

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARTEOLOL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; INCIDENCE; INSULIN RESISTANCE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; RAT;

EID: 0030907617     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01195.x     Document Type: Article

References (24)

1. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: The Framingham study. Ann. Intern Med. 1967; 67: 48-59.
2. Krone W, Nägele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am. Heart J. 1988; 116: 1729-34.
3. Nakamura H. Effects of anti-hypertensive drugs on plasma lipids. Am. J. Cardiol. 1987; 60: E24-8.
4. Nakagawa K, Murakami N, Yoshizaki S, Uno T, Shintani S, Nakagiri N. Derivatives of 3,4-dihydrocarbostyril as β-adrenergic blocking agents. J. Med. Chem. 1974; 17: 529-33.
5. Yahuuchi Y, Kinoshita D. Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy)propoxy-.3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent β-adrenergic blocking agent. Jpm. J. Pharmacol. 1974; 24: 853-61.
6. Yahuuchi Y, Hashimoto K, Yamashita S et al. Anti-arrhythmic properties of 5-(3-tert-butylamino-2-hydroxy)propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a newly synthesized, potent β-adrenoceptor antagonist. Clin. Exp. Pharmacol. Physiol. 1977; 4: 545-59.
7. Takahashi H, Nakano K, Yasuda T et al. Anti-obesity and anti-diabetic effects of carteolol in non-insulin-dependent diabetic mice. Clin. Exp. Pharmacol. Physiol. 1994; 21: 477-83.
8. Kawano K, Hirashima T, Mori S, Kurosumi M, Saitoh Y. A new rat strain with non-insulin dependent diabetes mellitus, 'OLETF'. Rat News Letter 1991; 25: 24-6.
9. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41: 1422-8.
10. Sato T, Asahi Y, Toide K, Nakayama N. Insulin resistance in skeletal muscle of the male Otsuka Long-Evans Tokushima Fatty rat, a new model of NIDDM. Diabetologia 1995; 38: 1033-41.
11. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991; 14: 1132-43.
12. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54-9.
13. Fujioka S, Matsuzawa Y, Tokunaga K et al. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int. J. Obes. 1991; 15: 853-9.
14. Day JL, Simpson N, Metcalfe J, Page RL. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. BMJ 1979; 1: 77-80.
15. Miller NE. Effects of adrenoceptor-blocking drugs on plasma lipoprotein concentrations. Am. J. Cardiol. 1987; 60: E17-23.
16. Morita S, Irie Y, Saitoh Y, Kohri H. Evaluation of a new beta-adrenergic blocking agent, carteolol, based on metabolic responses in rats-I. Biochem. Pharmacol 1976; 25: 1836-42.
17. Kataoka K, Mon K, Kiryu Y, Yasuda M, Takahashi K, Suzuki Y. Effects of carteolol on carbohydrate and lipid metabolism in patients with diabetes complicated by essential hypertension. Basic Pharmacol. Ther. 1984; 12: 1283-94.
18. Janczewski P, Boulanger C, Igbal A, Vanhoutte PM. Endothelium-dependent effects of carteolol. J. Pharmacol. Exp. Ther. 1988; 247: 590-5.
19. Vanhoutte PM. Endothelium-dependent effects of beta-adrenergic blockers. Blood Vessels 1990; 27: 301-5.
20. Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow: A possible link between insulin resistance and blood pressure. Hypertension 1993; 21: 129-35.
21. Arch JRS, Ainsworth AT, Cawthorne MA et al. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984; 309: 163-5.
22. 3-adrenoceptor agonist, BRL26830A, in yellow KK mice. Endocrinol. Jpn. 1991; 38: 397-403.
23. 3-adrenergic receptor. Mol. Pharmacol. 1993; 44: 1094-104.
24. 3-adrenoceptor agonist, in thermogenesis and increased blood flow in brown adipose tissue in anaesthetized rats. Clin. Exp. Pharmacol. Physiol. 1994; 21: 539-43.